MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development?

被引：68

作者：

O'Hagan, D. T. ^{[1
]}

Wack, A. ^{[1
]}

Podda, A. ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost Inc, Siena, Italy

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 82卷 / 06期

关键词：

D O I：

10.1038/sj.clpt.6100402

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.

引用

页码：740 / 744

页数：5

共 37 条

[31]

SIMON J, 2006, IMMUNOPOTENTIATORS M, P149

[32] A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens [J].